Ginkgo Bioworks Intrinsic Value Calculator – GINKGO BIOWORKS Reports Decrease in Revenue for Q3 of FY2023
November 22, 2023
🌥️Earnings Overview
For the third quarter of FY2023, GINKGO BIOWORKS ($NYSE:DNA) reported total revenue of USD 55.4 million, representing a 16.5% decrease from the same period in the previous year. Net income also decreased, coming in at USD -302.9 million compared to -669.1 million reported in Q3 of FY2022.
Price History
The stock opened at $1.6 and closed at $1.5, signifying a 3.2% drop from the previous closing price of $1.5. This decrease was seen as a surprise to many investors, who had expected the company to continue its trend of increasing revenue. As a result of the decrease in revenue, GINKGO BIOWORKS has revised its guidance and expects its full year earnings to be lower than initially estimated. In response to the decrease in revenue, GINKGO BIOWORKS has implemented several cost-saving measures.
The company has also announced the launch of new products and initiatives to generate additional revenue. Despite the decrease in revenue, GINKGO BIOWORKS remains optimistic and is confident that its long-term strategies will allow it to recover and continue to grow. The company’s management is confident that the company’s investments in new products and initiatives will pay off in the long run. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Ginkgo Bioworks. More…
| Total Revenues | Net Income | Net Margin |
| 314.99 | -859.79 | -232.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ginkgo Bioworks. More…
| Operations | Investing | Financing |
| -342.2 | -4.28 | 95.18 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ginkgo Bioworks. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.03k | 773.71 | 0.59 |
Key Ratios Snapshot
Some of the financial key ratios for Ginkgo Bioworks are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 106.6% | – | -232.8% |
| FCF Margin | ROE | ROA |
| -128.6% | -33.3% | -22.6% |
Analysis – Ginkgo Bioworks Intrinsic Value Calculator
At GoodWhale, we have conducted a comprehensive analysis of GINKGO BIOWORKS‘s financials. Our proprietary Valuation Line has calculated the intrinsic value of GINKGO BIOWORKS share to be around $4.0. This means that GINKGO BIOWORKS stock is currently being traded at $1.5, representing an undervaluation of 62.5%. As such, we believe there is tremendous potential for investors to capitalize on this opportunity. More…
Peers
The competition among Ginkgo Bioworks Holdings Inc and its competitors is fierce. Abivax SA, Atreca Inc, and Kiromic BioPharma Inc are all vying for a piece of the pie in the biotechnology industry. Ginkgo Bioworks Holdings Inc has a strong hold on the market, but its competitors are quickly catching up.
– Abivax SA ($OTCPK:AAVXF)
Abivax SA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies with the potential to transform the lives of patients suffering from chronic inflammatory diseases and cancer. The Company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
Abivax SA has a market cap of 178.76M as of 2022, a Return on Equity of -132.3%. The company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
– Atreca Inc ($NASDAQ:BCEL)
Atreca Inc is a biopharmaceutical company that focuses on the development of antibody-based therapeutics to treat cancer. As of 2022, its market cap is 59.43 million and its ROE is -86.67%. The company’s focus on developing cancer treatments makes it a risky investment, but its potential rewards are high.
– Kiromic BioPharma Inc ($NASDAQ:KRBP)
Kiromic BioPharma Inc is a clinical stage biopharmaceutical company that uses proprietary gene editing platform to develop cancer therapies. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Kiromic has a market cap of 5.32M as of 2022 and a Return on Equity of -127.9%. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Summary
Ginkgo Bioworks Inc. reported its financial results for the third quarter of FY2023, ending on September 30 2023, with total revenue of USD 55.4 million, a decrease of 16.5% from the same period in the previous year. The stock price reacted negatively to the announcement and dropped on the same day. Investors should consider that despite the lower revenue and income, Ginkgo Bioworks remains a leader in synthetic biology and is well positioned to capitalize on emerging trends in the industry. The company’s long-term performance will likely depend on its ability to develop and commercialize innovative products, optimize operations, and capitalize on growth opportunities.
